Osimertinib Cost Minimization in Non‐Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination with Cobicistat

Ähnliche Einträge

• Validation of a LC‐MS/MS Assay for Rapid and Simultaneous Quantification of Cobicistat and Venetoclax in Human Plasma and Serum
  von: Niels Westra, et al.
  Veröffentlicht: (2025)
• Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations
  von: Simone D. Baan, et al.
  Veröffentlicht: (2025)
• Concordance of Lung Cancer, Melanoma, and Renal Cell Cancer Diagnosis Information Recorded in Health Care Databases in England: Analysis of Linkage Between Primary Care, Hospital Care, and Cancer Registry Data
  von: Paul D. Kruithof, et al.
  Veröffentlicht: (2026)
• Reply to “High Pharmacokinetic Variability and Unrecognized Limitations in First‐Line Osimertinib Plus Chemotherapy for EGFR ‐Mutated NSCLC ”
  von: Azar Shahraz, et al.
  Veröffentlicht: (2025)
• Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC
  von: Jincheng Yang, et al.
  Veröffentlicht: (2025)